A Randomized Controlled Trial on the Safety and Efficacy of Exenatide Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes

Abstract

OBJECTIVEThis multicenter, open-label, randomized trial examined the safety and efficacy of exenatide alone or in combination with basal insulin in non-critically ill patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODSA total of 150 patients with blood glucose (BG) between 140 and 400 mg/dL, treated at home with diet, oral agents, or insulin at a total daily dose <0.5 units/kg, were randomized to exenatide alone (5 mg twice daily), exenatide plus basal insulin, or a basal-bolus insulin regimen. The primary end point was difference in mean daily BG concentration among groups. RESULTSMean daily BG was similar between patients treated with exenatide plus basal and a basal-bolus regimen (154 6 39 vs. 166 6 40 mg/dL, P = 0.31), and exenatide plus basal resulted in lower daily BG than did exenatide alone (177 6 41 mg/dL, P = 0.02). Exenatide plus basal resulted in a higher proportion of BG levels in target range between 70 and 180 mg/dL compared with exenatide and basal-bolus (78% vs. 62% vs. 63%, respectively, P = 0.023). More patients in the exenatide and exenatide plus basal groups experienced nausea or vomiting than in the basal-bolus group (10% vs. 11% vs. 2%, P = 0.17), with three patients (6%) discontinued exenatide owing to adverse events. There were no differences in hypoglycemia <54 mg/dL (2% vs. 0% vs. 4%, P = 0.77) or length of stay (5 vs. 4 vs. 4 days, P = 0.23) among basal plus exenatide, exenatide, and basal-bolus groups. CONCLUSIONSThe results of this pilot study indicate that exenatide alone or in combination with basal insulin is safe and effective for the management of hospitalized general medical and surgical patients with T2D.

Bacillus coagulans BC198 and Lactobacillus paracasei S38 in combination reduce body fat accumulation and modulate gut microbiota

“…It was also reported that the abundance of Firmicutes was positively associated with adiposity (Zhang et al, 2020). Nevertheless, other studies have found the negative or no correlation, suggesting that the association between obesity and gut microbiota were likely to be influenced by several factors (Fayrman et al, 2019). Thus, the relationship between the ratio of microbiota and obesity have so far been inconclusive.…”

15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes—2021

“…The safety and efficacy of noninsulin glucose-lowering therapies in the hospital setting is an area of active research (57,58). Several recent randomized trials have demonstrated the potential effectiveness of glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors in specific groups of hospitalized patients (59)(60)(61)(62). However, an FDA bulletin states that providers should consider discontinuing saxagliptin and alogliptin in people who develop heart failure (63).…”

Preoperative carbohydrate loading in diabetic patients undergoing gastrointestinal surgery: A pilot randomized trial

“…Hypoglycemia was de ned as blood glucose < 3.9 mmol/L, with or without symptom. Hyperglycemia was de ned as blood glucose > 13.3 mmol/L (Fayfman, et al, 2019;Pasquel, et al, 2017). Aspiration was de ned as gastric content appeared in the mouth and entered the trachea or lungs.…”